JP3009694B2 - 低用量ベナゼプリル／チアジド利尿薬組成物 - Google Patents
低用量ベナゼプリル／チアジド利尿薬組成物Info
- Publication number
- JP3009694B2 JP3009694B2 JP2010782A JP1078290A JP3009694B2 JP 3009694 B2 JP3009694 B2 JP 3009694B2 JP 2010782 A JP2010782 A JP 2010782A JP 1078290 A JP1078290 A JP 1078290A JP 3009694 B2 JP3009694 B2 JP 3009694B2
- Authority
- JP
- Japan
- Prior art keywords
- benazepril
- hydrochlorothiazide
- composition according
- thiazide diuretic
- low dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 15
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 title claims description 14
- 229960004530 benazepril Drugs 0.000 title claims description 14
- 239000003451 thiazide diuretic agent Substances 0.000 title description 12
- 229940121792 Thiazide diuretic Drugs 0.000 title description 10
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 21
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 15
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 claims description 8
- 229960003619 benazepril hydrochloride Drugs 0.000 claims description 8
- 239000005541 ACE inhibitor Substances 0.000 claims description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 3
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229960002155 chlorothiazide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960001523 chlortalidone Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000011162 core material Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HNLAFWZKHCUIMC-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O HNLAFWZKHCUIMC-UHFFFAOYSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- -1 hydrochloric Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229940082205 hydrochlorothiazide 25 mg Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30038389A | 1989-01-23 | 1989-01-23 | |
| US300383 | 1989-01-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02233616A JPH02233616A (ja) | 1990-09-17 |
| JP3009694B2 true JP3009694B2 (ja) | 2000-02-14 |
Family
ID=23158879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010782A Expired - Lifetime JP3009694B2 (ja) | 1989-01-23 | 1990-01-22 | 低用量ベナゼプリル／チアジド利尿薬組成物 |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JP3009694B2 (enExample) |
| KR (1) | KR0141479B1 (enExample) |
| AT (1) | AT401728B (enExample) |
| AU (1) | AU629288B2 (enExample) |
| BE (1) | BE1002736A4 (enExample) |
| CA (1) | CA2008126C (enExample) |
| CH (1) | CH680568A5 (enExample) |
| CY (1) | CY1835A (enExample) |
| DE (2) | DE4001496C2 (enExample) |
| DK (1) | DK175204B1 (enExample) |
| FR (1) | FR2641971B1 (enExample) |
| GB (1) | GB2227172B (enExample) |
| HK (1) | HK98995A (enExample) |
| IE (1) | IE61784B1 (enExample) |
| IL (1) | IL93117A0 (enExample) |
| IT (1) | IT1239744B (enExample) |
| LU (1) | LU87660A1 (enExample) |
| MX (1) | MX9203362A (enExample) |
| NL (1) | NL194958C (enExample) |
| NZ (1) | NZ232182A (enExample) |
| SA (1) | SA90100151B1 (enExample) |
| SE (1) | SE506179C2 (enExample) |
| SG (1) | SG176194G (enExample) |
| ZA (1) | ZA90429B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
| DK9200258U4 (da) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Farmaceutisk præparat indeholdende enalapril til brug mod hypertension |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| CN102579346B (zh) * | 2012-03-02 | 2013-09-25 | 海南美兰史克制药有限公司 | 贝那普利/氢氯噻嗪药物组合物脂质体固体制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4472380A (en) | 1978-12-11 | 1984-09-18 | Merck & Co., Inc. | Amino acid derivatives as antihypertensives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217347A (en) * | 1977-12-27 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Method of treating hypertension and medicaments therefor |
| US4410520A (en) * | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
| ZA833903B (en) * | 1982-06-01 | 1984-11-28 | Merck & Co Inc | Benzofused lactams as antihypertensives |
| US4520021A (en) * | 1982-07-02 | 1985-05-28 | Merck & Co., Inc. | Substituted caprolactam derivatives as antihypertensives |
-
1990
- 1990-01-08 SE SE9000050A patent/SE506179C2/sv not_active IP Right Cessation
- 1990-01-15 CH CH112/90A patent/CH680568A5/de not_active IP Right Cessation
- 1990-01-17 GB GB9001054A patent/GB2227172B/en not_active Expired - Lifetime
- 1990-01-18 LU LU87660A patent/LU87660A1/de unknown
- 1990-01-19 CA CA002008126A patent/CA2008126C/en not_active Expired - Lifetime
- 1990-01-19 DE DE4001496A patent/DE4001496C2/de not_active Expired - Lifetime
- 1990-01-19 DE DE2001199041 patent/DE10199041I1/de active Pending
- 1990-01-19 IT IT47548A patent/IT1239744B/it active IP Right Grant
- 1990-01-19 NZ NZ232182A patent/NZ232182A/en unknown
- 1990-01-19 FR FR909000612A patent/FR2641971B1/fr not_active Expired - Lifetime
- 1990-01-22 AT AT0013590A patent/AT401728B/de not_active IP Right Cessation
- 1990-01-22 NL NL9000158A patent/NL194958C/nl not_active IP Right Cessation
- 1990-01-22 KR KR1019900000697A patent/KR0141479B1/ko not_active Expired - Lifetime
- 1990-01-22 DK DK199000174A patent/DK175204B1/da not_active IP Right Cessation
- 1990-01-22 IL IL93117A patent/IL93117A0/xx not_active IP Right Cessation
- 1990-01-22 ZA ZA90429A patent/ZA90429B/xx unknown
- 1990-01-22 JP JP2010782A patent/JP3009694B2/ja not_active Expired - Lifetime
- 1990-01-22 AU AU48703/90A patent/AU629288B2/en not_active Expired
- 1990-01-22 IE IE23390A patent/IE61784B1/en not_active IP Right Cessation
- 1990-01-22 BE BE9000074A patent/BE1002736A4/fr not_active IP Right Cessation
- 1990-04-04 SA SA90100151A patent/SA90100151B1/ar unknown
-
1992
- 1992-06-25 MX MX9203362A patent/MX9203362A/es unknown
-
1994
- 1994-12-16 SG SG176194A patent/SG176194G/en unknown
-
1995
- 1995-06-22 HK HK98995A patent/HK98995A/xx not_active IP Right Cessation
- 1995-12-01 CY CY183595A patent/CY1835A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4472380A (en) | 1978-12-11 | 1984-09-18 | Merck & Co., Inc. | Amino acid derivatives as antihypertensives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6087386A (en) | Composition of enalapril and losartan | |
| EP1437131B1 (en) | Use of ramipril for the prevention of diabetes in a patient with no preexisting congestive heart failure | |
| HUP0400475A2 (hu) | Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| WO1998002183A1 (fr) | Compositions medicinales | |
| JP2002509540A (ja) | アルドースレダクターゼ阻害剤およびａｃｅ阻害剤を含有する医薬組成物 | |
| JP3009694B2 (ja) | 低用量ベナゼプリル／チアジド利尿薬組成物 | |
| EP0910375B1 (en) | A composition of enalapril and losartan | |
| HU205714B (en) | Process for producing hypotensive pharmaceutical compositions by using combination of angiotensin converting enzyme inhibitors and potassium canal modulator | |
| US4952410A (en) | Pharmaceutical products of moxonidine and hydrochlorothiazide | |
| KR19980702099A (ko) | 심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제와 부작용-감소된 양의 알도스테론 길항제의 조합 치료요법 | |
| RU2182002C2 (ru) | Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний | |
| CA2335280C (en) | Method of treating pulmonary hypertension | |
| AU767361B2 (en) | A method for the treatment or prevention of coronary graft vasospasm | |
| JP3454430B2 (ja) | ベラパミルおよびトランドラプリルを含有する製品 | |
| US4812455A (en) | Antiinflammatory compositions and methods | |
| IE43955B1 (en) | Pharmaceutical composition and dosage units thereof | |
| US20260021115A1 (en) | Synergistic combinations of Spironolactone, Finasteride, Dutasteride, and Minoxidil | |
| JP2621382B2 (ja) | 尿酸排泄剤 | |
| JPH1081632A (ja) | 医 薬 | |
| ITTO960379A1 (it) | Composizione farmaceutica per malattie cardiovascolari e renali. | |
| KR19980702100A (ko) | 심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제, 부작용-감소된 양의 알도스테론 길항제 및 이뇨제의 조합 치료요법 | |
| NZ199783A (en) | Sustained release compositions containing endralazine embedded in a wax matrix | |
| SA98190540B1 (ar) | جرعة مشتركة ثابتة تحتوي على مثبط لأنزيم تحويل الأنجيوتنسين وعلى عامل مضاد لقناة الكالسيوم لعلاج الأمراض القلبية الوعائية | |
| JP2008094852A (ja) | 医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081203 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091203 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 11 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 11 |